Merck : Announces Findings for Investigational Triple-Combination Chronic Hepatitis C Therapy Showing High Rates of Sustained Virologic Response in People with Genotypes 1, 2 or 3 Infection

Press/Media: Press / Media

PeriodNov 13 2016

Media coverage

4

Media coverage

  • TitleMerck : Announces Findings for Investigational Triple-Combination Chronic Hepatitis C Therapy Showing High Rates of Sustained Virologic Response in People with Genotypes 1, 2 or 3 Infection
    Media name/outlet4 Traders
    CountryUnited States
    Date11/13/16
    PersonsEric J Lawitz
  • TitleMerck Announces Findings for Investigational Triple-Combination Chronic Hepatitis C Therapy Showing High Rates...
    Media name/outletFreshnews.com
    CountryUnited States
    Date11/13/16
    PersonsEric J Lawitz
  • TitleMerck & Co Inc: Merck Announces Findings for Investigational Triple-Combination Chronic Hepatitis C Therapy Showing High Rates of Sustained Virologic Response in People with Genotypes 1, 2 or 3 Infection (Businesswire)
    Media name/outletAvanza Bank AB
    CountrySweden
    Date11/13/16
    PersonsEric J Lawitz
  • TitleMerck Announces Findings for Investigational Triple-Combination Chronic Hepatitis C Therapy Showing High Rates of Sustained ...
    Media name/outletEIN News
    CountryUnited States
    Date11/13/16
    PersonsEric J Lawitz